December 8, 2021
Sumitomo Dainippon Pharma on December 7 established a wholly owned subsidiary in Malaysia with an eye to the launch of its approval-pending atypical antipsychotic Latuda (lurasidone) in 2022. The company said on December 7 that the new subsidiary, Sumitomo Pharma...read more